GSK Q1 2017 results

34.4%Driven by growth of new products, partly offset by divestments

Strong performances in oral health and cold & flu partly offset by disposal, continuing weakness in some international markets and late start to allergy season

Continued momentum from meningitis and established vaccines

Improved Group operating margin

GSK Group Sales growth across all three businesses

Free cash flow

Sales

£7.4bn £4.2bn

£1.2bn

£0.7bn

17.2%

See press release on www.gsk.com for details on Q1 2017Please read this cautionary statement regarding forward-looking statements

Pharmaceuticals

Vaccines

Consumer Healthcare

Operating margin+17% AER | +4% CER+19% AER | +5% CER

>100% AER>100% CER

+31% AER | +9% CER 29.6%Operating margin+31% AER | +16% CER

Operating margin£2.0bn+16% AER | +2% CER

Total EPS Adjusted EPS

21.4p 25.0p